Abacam signed a Memorandum of Understanding with Shuwen Biotech

| By | Medical Devices, R&D
0
144

Abcam, a global leader in the supply of life science research tools, signed a Memorandum of Understanding (MoU) with Shuwen Biotech, a leading player in the development and commercialization of companion diagnostics (CDx). 

Through the agreement, Abcam and Shuwen will jointly leverage their respective capabilities, in producing high-quality antibodies and CDx kit development and commercialization, to better serve the needs of the pharma industry.

The two parties are responding to the increasing range of development needs from pharmaceutical and biopharma developers, patients, healthcare professionals, and regulatory authorities, The nature of any joint work is yet to be determined in detail but is likely to encompass Abcam providing reproducible highly-specific recombinant antibodies to key targets, which Shuwen will incorporate into companion diagnostic kits.

Shuwen Biotech is a China-based diagnostics company founded on the principles of innovation, patent protection, and international collaboration as its strategic platforms for growth. Since 2011, Shuwen established strategic partnerships with numerous outstanding academic and commercial institutions such as Yale University, University of Chicago, Max-Plank Institute, BioNTech among others in the form of exclusive licensing of over 20 first-in-class diagnostic technologies and 50+ patents covering a range of novel biomarkers for companion diagnostics and other diagnostics in the fields of cancer, women’s health, critical care, and health screening and other fields.

SOURCE: abcam
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.